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Cytotoxic drug induced nausea and vomiting is one of the
most notorious problems associated with the chemotherapy
of malignant disease. The classical experiments of Borison
and Wang (1953) first published in the late 1940s and during
the 1950s, provided a scientific basis for the physiological
concepts of a vomiting centre (VC), a chemoreceptor trigger
zone (CTZ) and some of the pathways involved. However,
until the late 1960s, anti-emesis in the cancer field was largely
empirical and often poorly effective. The pioneering clinical
studies of Gralla et al. (1981) and Sallan et al. (1980) into the
use of high-dose metoclopramide and the cannabinoids
respectively provided not only a scientific framework for
conducting anti-emetic studies but also demonstrated
significant advances in anti-emetic control. The rational
implementation of anti-emetic therapy should be based upon
scientific data and hence it is appropriate to summarise the
current state of knowledge.
Vomiting is recognised to be in physiological terms a
protective mechanism for removing harmful substances which
have been accidentally ingested. Animals such as rats with a
highly developed olefactory apparatus do not vomit as
accidental ingestion is presumably highly unlikely. However,
a useful animal model for anti-emetic work has been found
to be the ferret. In this model the initial response to noxious
compounds is initiated in the gut. A second line of defence
occurs when the substance penetrates the systemic circulation
and a chemosensitive detector provides a signal to initiate
vomiting. Both cytotoxic drugs and radiation may stimulate
emesis by acting as peripheral (gut) or central (CTZ) 'toxins'.
Trigger signals are then relayed to the vomiting centre
(VC), which co-ordinates the final common pathway vomit-
ing reflexes.
It is a common experience that pain, motion, visual
stimuli, sounds or psychological messages via other pathways
can also stimulate the vomiting centre. Therefore, the learned
aversion process which helps protect the host against harmful
repetitive ingestion is also the basis for anticipatory nausea
and vomiting in man.
The CTZ is known to be a specialised group of cells in the
area postrema. This area is in intimate contact with both
cerebrospinal fluid and blood, being effectively outside the
blood-brain barrier.
Recent work has questioned the exact location of the VC;
however, the general area of location does appear to be the
brain stem in the reticular formation. The vomiting centre is
therefore best considered physiologically rather than
anatomically as a discrete neurological locus. As anti-
cholinergics are effective against motion sickness only, this
supports the concept that a variety of neurotransmitters are
involved in the different signals afferent to the VC, although
there may be one afferent common final pathway. However,
as yet, this is also uncertain. The discovery that dopamine-
receptor antagonists, such as apomorphine, regularly
evoked vomiting led to the development of many anti-
dopaminergic compounds as anti-emetics. These compounds
have often been used alone or in combination with opiate
antagonists such as the cannabinoids. The widely used anti-
dopaminergic drugs, such as the phenothiazines and meto-
clopramide, have been found to have additional modes of
action. The improved clinical results of high dose meto-
clopramide led to the discovery that at these concentrations it
acted as an antagonist of the 5-hydroxytryptamine receptor
(5HT3 or M receptors). Receptors of the 5HT3 type have
been characterised using isolated peripheral tissue models,
such as the rat vagus nerve, guinea pig ileum and isolated
rabbit heart. These data led to the search for 5HT3 receptor
antagonists. To date, four such compounds have come to
clinical trial: GR 38032F, Ondansetron (Glaxo); BRL 43694,
Granisetron (Beecham); ICS 205-930 (Sandoz); and MDL
72222 (Merck, Sharp and Dohme). Although some data
suggested the presence of 5HT3 receptors centrally, it is only
recently that such receptors have been identified in rat brain
with particularly high concentrations in cortical and limbic
areas (Kilpatrick et al., 1987).' It has also been shown that
antagonists of 5HT3 receptors compete for central binding
sites with affinities that correspond to their affinities in func-
tional 5HT3 receptor models. Unlike metoclopramide, 5HT3
antagonists do not possess any dopamine-blocking activity
and so are free of the extrapyramidal side-effects which are
particularly troublesome especially in younger patients.
The early clinical trials by Cunningham et al. (1987) of the
5HT3 receptor antagonists confirmed an excellent side-effect
profile with excellent protection from emesis due to non-
platinum containing regimes. When cisplatin containing
regimes are used, particularly at high dose, major control of
emesis seems to be achieved in about two-third to three-
quarters of the subjects. (Proceedings ECCO Meeting
London, 3-7 September 1989). These results are similar to
the results of optimum conventional combination anti-emetic
therapy but probably with a superior side-effect profile. More
work is necessary with the 5HT3 antagonist compounds to
optimise dose and schedule. Certainly the scene is set for
further randomised control trials against conventional anti-
emetic schedules and to begin to use 5HT3 antagonist com-
pounds in combination anti-emetic studies.
Seigal and Longo (1981) reviewed the efficacy of many of
the so-called standard compounds against nausea and
vomiting and concluded that the anticholinergics, the antihis-
tamines and low-dose metoclopramide were ineffective as
anti-emetics for cytotoxic drugs.
Phenothiazines are still widely used despite problems of
bioavailability but randomised trials have shown both high-
dose metoclopramide and nabilone (a synthetic cannabinoid
derivative) to be superior to prochlorperazine. The
phenothiazines remain moderately effective against mildly
emetogenic chemotherapy.
The precise mechanism of action of the cannabinoids is
uncertain because of our poor knowledge of the probable
opiate receptors and their physiology. The major side-effect
of the cannabinoids is dysphoria, more problematic in older
patients, although concomitant phenothiazine can reduce this
problem. Nabilone, the most widely used derivative of this
Correspondence: R.C.F. Leonard.
Received 17 October 1989; and in revised form 30 October 1989.350 R.C.F. LEONARD & M. SOUKOP
group, is sometimes effective even against 'low dose'
cisplatin-induced vomiting.
High dose metoclopramide provided the impetus for many
of the current studies because of its dramatic effect against
cisplatinum induced vomiting. In the past 5 years
modifications of the technique of delivery of metoclopramide
have been followed from pharmacological studies in the UK
and currently recommended practice is to give bolus plus
continuous infusion therapy either alone or in combination
with a corticosteroid.
The first reports of the value of corticosteroids against
cytotoxic vomiting were produced by Cassileth who demon-
strated the activity of dexamethasone. The mechanism of
action of glucocorticoids is uncertain but they appear to be
valuable additional compounds for combination anti-emetic
therapy, particularly with high dose metoclopramide. Often
benzodiazepines are used in combination and lorazepam is
currently the most widely selected compound. Ben-
zodiazepines may well affect the vomiting reflex by depres-
sing higher cerebral centres and again may be most usefully
employed in combination anti-emetic therapy. The develop-
ment of combination anti-emetic therapy, however, carries its
own dangers with the problems of drug interactions, not only
between the anti-emetics themselves but between the anti-
emetics and cytotoxic agents either by direct interaction or
more likely by altering the pharmacokinetics of the cytotoxic
drugs.
The problem of anticipatory emesis is closely correlated
with lack of good anti-emetic control with initial courses of
chemotherapy. Morrow (1984) has identified a number of
factors important in developing anticipatory nausea and
vomiting including severity of post-chemotherapy vomiting,
duration of nausea and number of courses of therapy with
poorly controlled emesis. Recommendations have been made
to reduce associated trigger factors such as having follow-up
clinics in a different area to the treatment area and reducing
distinctive features of treatment sites such as avoidance of
strong-smelling cleaning fluids or air fresheners. The use of
relaxation techniques and behaviour modification may also
be very beneficial in some patients but are time-consuming
and require experienced staff. The best method to prevent
anticipatory problems is, however, good initial anti-emetic
control and the early recognition of a developing problem in
which context the use of benzodiazepines providing short-
term memory loss and sedation may be very beneficial.
Recent developments, both in new anti-emetics and better
ways of using the existing ones, lead us to cautious optimism
that nausea and vomiting due to cancer chemotherapy can be
reduced substantially with considerable benefit to the
patient.
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